May 21 |
Peering Into ZyVersa Therapeutics's Recent Short Interest
|
May 15 |
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
|
May 14 |
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
|
Apr 29 |
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
Apr 29 |
What's Going On With ZyVersa Stock?
|
Apr 26 |
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
|
Apr 4 |
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
|
Mar 25 |
ZyVersa Therapeutics GAAP EPS of -$0.29
|
Mar 25 |
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
|
Mar 18 |
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediatorâ„¢ VAR 200 in Patients with Diabetic Kidney Disease
|